22:48 , May 25, 2018 |  BC Extra  |  Company News

Management tracks: ISA, ImCheck, ArQule

Immunotherapy company ISA Pharmaceuticals B.V. (Leiden, the Netherlands) promoted CBO Gerben Moolhuizen to CEO, effective June 1. He succeeds CEO Ronald Loggers. Also in May, ISA hired Leon Hooftman as CMO. Hooftman was CMO at...
15:16 , Mar 30, 2018 |  BC Week In Review  |  Clinical News

Allecra reports Phase II data for AAI101 combo to treat cUTI

Allecra Therapeutics GmbH (Lörrach, Germany) reported top-line data from the Phase II CACTUS trial in 45 hospitalized adults with complicated urinary tract infections (cUTIs), including pyelonephritis, showing that AAI101 in combination with cefepime was well...
17:33 , Mar 2, 2018 |  BC Week In Review  |  Financial News

BioMedPartners closes third fund at CHF100M

BioMedPartners (Basel, Switzerland) closed its BioMedInvest III fund at CHF100 million ($107 million). The firm plans to invest the fund in 12-15 private early to mid-stage pharmaceutical, medical device and diagnostics companies in Switzerland, Germany...
18:11 , Mar 1, 2018 |  BC Extra  |  Financial News

BioMedPartners closes third fund

BioMedPartners closed its BioMedInvest III fund at CHF100 million ($107 million). The firm plans to invest the fund in 12-15 private early to mid-stage pharmaceutical, medical device and diagnostics companies in Switzerland, Germany and neighboring...
23:24 , Apr 6, 2017 |  BC Extra  |  Company News

Management tracks

Sanofi (Euronext:SAN; NYSE:SNY) said David Meeker will resign as EVP of its Sanofi Genzyme unit at the end of June. The company promoted Bill Sibold to the position, effective July 1. Sibold is head of...
07:00 , Jun 20, 2016 |  BC Week In Review  |  Financial News

Allecra completes venture financing

Allecra Therapeutics GmbH , Lorrach, Germany   Business: Infectious   Date completed: 2016-06-15   Type: Venture financing   Raised: EUR22 million ($24.8 million)   Investors: Delos Capital; Forbion Capital Partners; Edmond de Rothschild Investment Partners;...
01:20 , Jun 16, 2016 |  BC Extra  |  Financial News

Antibiotic play Allecra raises EUR 22M

Allecra Therapeutics GmbH (Lorrach, Germany) raised EUR 22 million ($24.8 million) in an untranched series B round led by new investor Delos Capital. Existing investors Forbion Capital Partners, Edmond de Rothschild Investment Partners, EMBL Ventures...
08:00 , Feb 20, 2014 |  BC Innovations  |  Cover Story

Europe's upwelling

SciBX 's third annual comprehensive analysis of public-private partnerships and early stage venture financing activity shows that Europe's public-private partnership activity in 2013 surpassed that of the U.S. in dramatic fashion. At least 314 companies...
08:00 , Nov 4, 2013 |  BioCentury  |  Finance

Rothschild racks up

Edmond de Rothschild Investment Partners is sticking with its investment strategy for the firm's fourth dedicated life sciences fund - an approach that has allowed it to return money to LPs every year since 2004...
07:00 , May 13, 2013 |  BioCentury  |  Emerging Company Profile

Allecra: Secret weapon vs. bacteria

Allecra Therapeutic GmbH aims to develop a broad-spectrum solution to multidrug-resistant Gram-negative bacteria. The company will advance at least two preclinical compounds acquired from Orchid Chemicals & Pharmaceuticals Ltd. , an Indian pharma, for a...